Stronvivo is an Informed Choice certified nutritional supplement comprised of natural, USP-verified, pharmaceutical-grade ingredients designed to improve the health of the endothelium, stimulate the production of nitric oxide, improve circulation, increase blood flow, boost energy and inhibit platelet aggregation and adherence, all of which play an integral role in both male and female sexual function.

Stronvivo is an effective treatment for female sexual dysfunction. stronvivo increases sexual desire, sexual arousal, orgasm satisfaction and lubrication.

Stronvivo improves erectile function and sexual desire for men.
 
Stronvivo is safe, natural, certified and effective.

Stronvivo Clinical Trial Results

Using the below-listed clinical tools, stronvivo demonstrated statistically significant improvements in both male and female sexual functioning.

For men, Stronvivo improved erectile functioning and increased sexual desire. 

For women, Stronvivo increased sexual desire, increased sexual arousal, improved orgasms (frequency and pleasure), increased satisfaction, improved lubrication and reduced pain.

Stronvivo Clinical Tools and Scores

FSFI (Female Sexual Functioning Index), a 19-item questionnaire, has been developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual function in women. It was developed on a female sample of normal controls and age-matched subjects who met DSM-IV®-TR criteria for female sexual arousal disorder (FSAD) and provides scores on six domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) as well as a total score. The FSFI has been validated on clinically diagnosed samples of women with female sexual arousal disorder (FSAD), female orgasmic disorder (FOD), and hypoactive sexual desire disorder (HSDD). See also FSFI Validation authored by Wiegel MMeston CRosen R.

Statistically Significant Changes; increased scores indicate improvement in sexual function:
  FSFI Full Scale Score +12.05
  FSFI Desire +2.10
  FSFA Arousal +2.30
  FSFI Lubrication +2.28
  FSFI Orgasm +2.00
  FSFI Satisfaction +1.45
  FSFI Pain +2.15

Stronvivo Clinical RESULTS

FSFI participants were divided into two groups:
Group 1: FSFI Full Scale baseline mean = 12.967
Group 2: FSFI Full Scale baseline mean = 23.740
Time points 1, 2, 3 and 4 represent Baseline, 30 days, 60 days and 90 days, respectively.
FSFI Full Scale Score, Stronvivo improves sex, female sexuality, female sexual function, female sexual dysfunction
FSFI Desire, Stronvivo improves desire, female sexuality, female sexual function, female sexual dysfunction
FSFI Arousal, Stronvivo improves Arousal, female sexuality, female sexual function, female sexual dysfunction
FSFI Lubrication, Stronvivo improves lubrication, female sexuality, female sexual function, female sexual dysfunction
FSFI Orgasm, Stronvivo improves orgasm, female sexuality, female sexual function, female sexual dysfunction
FSFI Satisfaction, Stronvivo improves sex satisfaction, female sexuality, female sexual function, female sexual dysfunction
FSFI Pain, Stronvivo decreases pain, female sexuality, female sexual function, female sexual dysfunction

IIEF (International Index of Erectile Function) is designed to assess for treatment-related changes among patients with erectile dysfunction. The questionnaire contains 15 items that are rated on a 6-point Likert scale, which assess four domains of male sexual dysfunction: erectile function, orgasmic function, sexual desire, and intercourse satisfaction. See also IIEF Validation authored by Rosen RCRiley AWagner GOsterloh IHKirkpatrick JMishra A.

Statistically Significant Changes (increased scores indicate improvement in sexual function):
  IIEF Full Scale Score +8.75
  IIEF Erectile Function +3.49*
  IIEF Sexual Desire +1.42
  IIEF Overall Satisfaction +1.77
*IIEF participants with low erectile function baseline scores (<14) exhibited a statistically significant improvement of +6.52 in the erectile function domain and a statistically significant improvement of +2.41 in the sexual desire domain. Both improvements exhibited at the 60 day evaluation point.
 

PHQ-9 (Patient Health Questionnaire) is widely used in primary care clinics, outpatient offices, and longitudinal research studies to monitor a patient’s symptoms of depression. This questionnaire is comprised of 9 items that correspond with the diagnostic criteria for depression included in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) [12]. Each statement is rated on a 4-point, Likert scale.

PHQ-9 results exhibited statistically significant improvements in depressive symptoms occurred for males after 30 days and for females after 60 days. These improvements from baseline were maintained at the 60 and 90 day follow-up, respectively. Decreased scores indicate reduction in symptoms of depression.

stronvivo PHQ-9 lower depression in women and men

ADAM (Androgen Deficiency in Aging Males) is designed to assess for symptoms of low testosterone.

ADAM - over half (51.2%) of the men meeting criteria for androgen deficiency at baseline no longer met criteria after 30 days of stronvivo supplementation. The percentage held constant at 60 days. After 90 days of stronvivo supplementation, 55.8% of the men meeting criteria for androgen deficiency at baseline no longer met criteria. The labeled/green areas indicate the percentage of men whose ADAM results indicated androgen deficiency at Baseline who subsequently indicated not likely to be androgen deficient after taking stronvivo for the time period noted on the x-axis.

stronvivo lowers ADAM score, not androgen deficient after 30 days

(See published results: Journal of Sexual MedicineInternational Society for the Study of Women's Sexual Health and here.)

Order Now